EMA CVMP meeting highlights – 13–14 January 2026

21st January 2026

EMA CVMP meeting highlights – 13–14 January 2026

Summary: At its 13–14 January 2026 session, the CVMP adopted a positive opinion for a new marketing authorisation for a combination product (lotilaner/milbemycin) for dogs at risk of multiple parasitic infections. The Committee also issued positive opinions on several quality-related variations and worksharing procedures for existing veterinary products. A re-examination was recommended for the bluetongue vaccine Bluevac-3, extending its authorisation validity for one year under exceptional circumstances. Scientific advice reports were adopted for two veterinary pharmaceutical products for dogs and cats. Under limited market classification, a musculoskeletal product intended for horses was deemed not eligible for authorisation under Article 23 of Regulation (EU) 2019/6. The CVMP also moved several guideline updates and concept papers into public consultation, including revised efficacy guidelines for ectoparasiticides and for products controlling Varroa destructor in honeybees, and a concept paper on using owner assessment as an efficacy parameter. Other revised guidelines were agreed to align with current legislation — covering combined vaccines, environmental risk for immunologicals, user safety for immunological products and fish vaccine study design. The Committee also adopted updated questions and answers on quality topics such as titanium dioxide, co-processed excipients and use of CEPs to reflect recent legislative and scientific developments.

Link: https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-13-14-january-2026

Back to Recent News